Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04917770
Other study ID # HX20210601
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 30, 2021
Est. completion date June 30, 2024

Study information

Verified date June 2021
Source West China Hospital
Contact Xingchen Peng, Ph.D
Phone 18980606753
Email pxx2014@scu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nasopharyngeal carcinoma is the most common malignant tumor of head and neck in southern China. After standard treatment, about 20% of the patients had local recurrence or distant metastasis, and the patients faced death in a short time. Currently, there is no recommended treatment for patients with recurrent or metastatic nasopharyngeal carcinoma who have unsatisfactory results of first-line chemotherapy and subsequent immunotherapy. Patients who have failed multiline therapy have a low survival rate and no drugs are available.This project aims to evaluate the efficacy and safety of sintilimab in combination with multimodal radiotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma who have previously received immunotherapy and still progress after multiline therapy, and to seek a new therapeutic approach for such patients.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 28
Est. completion date June 30, 2024
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. The histopathological diagnosis was recurrent or distant metastatic nasopharyngeal carcinoma; 2. Have received two or more lines of treatment, including at least one immunocheckpoint inhibitor related therapy containing PD-1/L1, and have achieved clinical benefit; 3. Aged between 18 and 65 at the date of signing the informed consent; 4. ECOG score 0-1; 5. At least =1 measurable lesion according to Recist v1.1, or =1 measurable lesion with definite progression after local treatment (based on Recist v1.1 criteria);At the same time, there were more than 1 radiotherapy foci and lesions with radiographic evaluation of distant effect. 6. Life expectancy =12 weeks; 7. Major organ functions within 28 days prior to treatment meet the following criteria: A. Routine blood test criteria (without blood transfusion within 14 days) : hemoglobin (Hb) =80g/L;Neutrophils absolute value (ANC) =1.5×109/L;Platelet (PLT) =80×109/L; B. Biochemical tests should meet the following criteria: total bilirubin (TBIL) =1.5 times the upper limit of normal (ULN);Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5×ULN, if accompanied by liver metastasis, ALT and AST=5×ULN;Serum creatinine (CR) =1.5×ULN or creatinine clearance rate (CCR)=60ml/min; C. Coagulograms should meet the following criteria: International Standardized Ratio (INR) or Prothrombin Time (PT) = 1.5ULN;Activated partial thromboplastin time (APTT) =1.5 ULN (if the patient is receiving anticoagulant therapy, as long as PT and APTT are within the expected treatment range); D. centrifuge markers and urinary natriuretic peptide (BNP) =ULN; E. Thyroid function: T3 and T4 levels were normal after medication; 8. Women of reproductive age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and for 120 days after the end of the study;Negative serum or urinary pregnancy test within 7 days prior to study enrollment; 9. With my consent and signed the informed consent. Exclusion Criteria: 1. Previous use of immunocheckpoint inhibitors combined with radiotherapy after recurrence and metastasis; 2. A history of other malignant tumors within the previous 5 years or at the same time, except cured basal cell carcinoma of the skin, carcinoma in situ of the cervix and papillary carcinoma of the thyroid; 3. known allergic reactions to active ingredients of PD-1 monoclonal antibody or any excipients; 4. Symptomatic central nervous system metastasis; 5. Those who had received potent CYP3A4 inhibitor treatment within one week before enrollment, or inducer CYP3A4 treatment within two weeks before enrollment; 6. The New York Heart Association's cardiac function classification is Grade III-IV congestive heart failure; 7. An ischemic cardiovascular event occurred within 1 year prior to treatment; 8. QT interval of ECG >500 ms; 9. Have received systemic immunosuppressive therapy; 10. Participate in clinical trials of other interventional drugs within 4 weeks before the first administration; 11. Subjects who require systematic treatment with corticosteroids (greater than 10mg equivalent daily dose of prednisone) or other immunosuppressant within 2 weeks prior to the first use of the study drug; 12. Have received an anti-tumor vaccine or a live vaccine within 4 weeks before the first administration of the investigational drug; 13. Major surgery or severe trauma within 4 weeks before the first use of the study drug; 14. Severe infections (CTCAE > grade 2) occurred within 4 weeks before the first use of the study drug, such as severe pneumonia, bacteremia, infection complications, etc., requiring hospitalization;Baseline chest imaging examination suggests active pulmonary inflammation, signs and symptoms of infection within 2 weeks prior to the first use of the study drug, or the need for oral or intravenous antibiotic treatment (excluding prophylactic use of antibiotics); 15. Have a history of active autoimmune diseases or autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes);Autoimmune-mediated hypothyroidism treated with a steady dose of thyroid-replacement hormone and with a steady dose of insulin in type 1 diabetes were included;This does not include patients with vitiligo or cured childhood asthma/allergies who do not need any intervention as adults; 16. Have a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation or bone marrow transplantation; 17. History of non-infectious pneumonia 18. Patients with active tuberculosis infection found by medical history or CT examination, or patients with active tuberculosis infection found within 1 year before enrollment, or patients with active tuberculosis infection found before 1 year but without formal treatment; 19. Subsubjects had active hepatitis (HBV DNA=2000IU/ mL or 10000 copies/ mL) and hepatitis C (HCV antibody positive and HCV-RNA above the detection limit of the assay method); 20. A history of known abuse of psychotropic substances, alcoholism and drug abuse; 21. Being pregnant or lactating; 22. There is any history, disease, treatment, or abnormal laboratory result that may interfere with the results of the study and prevent subjects from participating fully in the study, or the investigator deems that participation is not in the best interest of the subjects.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sintilimab in combination with Multimodality Radiotherapy
Participants will be treated with sintilimab in combination with multimodality radiotherapy

Locations

Country Name City State
n/a

Sponsors (6)

Lead Sponsor Collaborator
West China Hospital Chengdu City No.2 People's Hospital, No.3 People's Hospital of Chengdu, No.5 People's Hospital of Chengdu, Sichuan Provincial People's Hospital, The First People's Hospital of Ziyang

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate up to approximately 2 years
Secondary Progression-free survival up to approximately 2 years
Secondary Overall survival up to approximately 2 years
Secondary Duration of remission up to approximately 2 years
Secondary 1 year overall survival 1 years after treatment finished
Secondary Adverse reactions Time Frame: from the first drug administration to within 30 days for the last therapy
See also
  Status Clinical Trial Phase
Recruiting NCT05979961 - Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT06055816 - Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05547971 - Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
Not yet recruiting NCT05020925 - SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 1/Phase 2
Not yet recruiting NCT04547088 - Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT04548271 - Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02795169 - Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02569788 - Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02801487 - Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Completed NCT02237924 - Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02044562 - Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients N/A
Terminated NCT01694576 - NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation Phase 2
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01271439 - Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma Phase 2
Completed NCT00535795 - Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Phase 3
Completed NCT00379262 - Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma Phase 3
Completed NCT03398980 - Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy N/A
Completed NCT01309633 - Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) Phase 2